Introduction
Translating our understanding of the re generative capacity of the adult kidney into treatments for acute kidney injury (AKI) and chronic kidney disease (CKD) is a high priority in nephrology. Although nephrons can undergo cellular regeneration in response to damage, the kidney has no capa city for structural regeneration as no new nephrons form after birth. As a result, the focus of research has been on the source, location and reparative capacity of endo genous renal cells and their contribution to tubular repair.
The innate capacity of the kidney to regenerate has been best established in AKI, where resident tubular epithelial cells that survive a given damage dedifferentiate and subsequently reenter the cell cycle and replace the necrotic tubular epithelium. 1 More recently, glomerular epithelial repair, involving resident multipotent progeni tor cells in the parietal epithelium of the Bowman capsule, has been described. 2 Lineage analyses have confirmed the tubular location of cells that contribute to nephron repair, but debate exists as to whether these cells represent a stem cell population within the tubules or dedifferentiated adult epithelial cells. 2, 3 What is clear is that cellular regeneration is ineffective in the face of chronic insult, and our ability to harness endogenous repair mechanisms is still far from clini cal application. Although interstitial renal stem cell populations had been proposed to incorporate into the tubular epithelium during repair, 4 this mechanism does not seem to occur. 5 However, mesenchymal stromal cells (MSCs) are now understood to support epithelial repair by providing signals, such as cytokines and exosomes, which favour tubular regeneration over inflammation. 6 This effect of support ing epithelial repair can be achieved both with autologous and allogeneic MSCs, and has been attributed to the immunological properties of MSCs. Although MSCs were initially considered to possess substantial inherent plasticity and regenerative poten tial, the consensus today is that the thera peutic effects of MSCs in the kidney are caused by paracrine effects.
Although the initial success of a clinical trial using bonemarrowderived MSCs to treat acute renal damage is promising, 7 the overall utility of MSCs is compromised by our limited understanding of how these cells function. The identification of an endo genous renal MSC population that may have a homeostatic role in situ raises the possi bility that the kidney itself contains all the elements required to balance the processes of tissue repair and damage.
This Perspectives article focuses on the interaction between cells in the renal inter stitium and the tubular compartment, with the aim of integrating historical experi mental findings in nephrology with current understanding of progenitor cell biologytwo areas that have previously been con sidered separately. A better understanding of how to harness the regenerative capa city of the kidney is required to succeed in driving effective cellular repair in CKD.
Tubular cell regeneration
The fact that renal tubules can regenerate epithelial cells after acute ischaemic or toxic insult has long been appreciated. Indeed, extensive tubular necrosis, such as can occur during ischaemic insults to the kidney, can resolve without any residual damage. This finding was classically considered to involve the dedifferentiation of the adult epithelial cells that survived the insult via epithelial tomesenchymal transition (EMT). These cells were then thought to redifferentiate via the opposite mechanism-mesenchymeto epithelial transition (MET)-before prolif erating. One study has shown that renal epithelial cells are poised in the G1 phase of the cell cycle (cyclin D1positive), making them ready to respond to injury via pro liferation. 8 Within 2 days of damage, over 50% of medullary tubular cells express the proliferation marker, Ki67, 9 supporting the dedifferentiation model. Despite these observations, an alternative explanation has evolved in which a stemcelllike sub population present within the renal tubules is responsible for the reepithelialization. 2, 10 Both of the above explanations suggest that the cells involved in regeneration share a common ancestry. Indeed, initial nephron formation involves a progenitor mesenchyme, the cap mesenchyme, which undergoes MET (Figure 1 ). The process of nephron formation is evolutionarily Abstract | The ageing population and the increasing prevalence of noncommunicable diseases such as diabetes and hypertension have led to an increased prevalence of chronic kidney disease. The generation of de novo kidney tissue from embryonic tissue and stem cells using tissue engineering approaches is being explored as an alternative to renal replacement therapy for treating the disease. It is, however, becoming clear that resident cells can not only induce fibrotic repair, but can also restore damaged kidney tissue. Mobilizing this innate capacity of the kidney to regenerate is of particular interest in the prevention of irreversible kidney failure. A novel concept is that the interaction of interstitial stromal cells with the local immune system may regulate tissue homeostasis and the balance between tissue repair and fibrosis. Mesenchymal stromal cells (MSCs), in particular, may enhance the intrinsic reparative capabilities of the kidney. This Perspectives article considers the innate regenerative potential of the kidney in the context of ongoing studies of MSC therapy.
conserved such that the functional fil tration unit is created via MET even in organisms in which a metanephric or permanent kidney does not form. 2, 11, 12 Proof that it is this tubular compartment, derived from homeobox protein Six2 expressing cap mesenchyme cells, which retains the capacity for renewal in adult life was established using a transgenic Six2GFPCre mouse strain (in which all cap mesenchymederived epithelium are labelled with GFP). 5 After induction of AKI in adult animals, no evidence of diluted labelling of the nephron epithelia with noncapmesenchymederived cells was found, demonstrating that the tubular epithelial cell proliferation associated with recovery from AKI does not involve cell populations outside of the renal tubular epithelium. However, this study did not resolve the question of whether a stem cell subpopulation that is primed to respond to injury exists in the renal tubules (Figure 1a) or whether all adult epithelial cells could, if able to survive the initial insult, return to a more primitive state from which regeneration could occur (Figure 1b) . In support of the stem cell model, several studies have proposed the existence of epithelial cells with stem cell properties, including a CD133 (also known as Prominin 1)positive population within the loops of Henle in the human kidney. 13, 14 These CD133
+ cells also express a number of genes encoding stem cell markers, and in vitro upregulate Oct4 in response to hypoxia and show the capacity to form a variety of renal epithelial structures.
14 A distinct epithelial cell population, characterized by the expression of CD24 and CD133 surface markers, has also been isolated from the proximal tubules and from the visceral epithelium of the Bowman capsule. 10, 15, 16 Although podocyte loss has traditionally been considered to be irreparable, evidence exists to suggest that progenitors along the Bowman capsule can act as a reser voir of cells that contribute to the turn over of damaged podocytes. Although this process would provide a mechanism for podocyte replacement, severe podocyte damage seems to implicate these progeni tors in an aberrant repair process, with an excessive proliferative response contrib uting to the development of hyperplastic lesions and/or crescent formation. [18] [19] [20] As mentioned earlier, the alternative to the theory of a resident stem cell population is that these cellular phenotypes represent a dynamic process of dedifferentiation avail able to all cells in the tubule (Figure 1b ). In support of this theory, evidence suggests that during the repair process almost 70% of the tubular epithelium undergoes cell division, suggesting that the repair process is not mediated by a rare subpopulation of cells. 9 Although present and detectable, CD24 + CD133 + epithelial cell populations are rare in healthy human kidneys and undetectable in healthy rodent kidneys, only appearing after injury. 3 This subpopulation of cells in human tissue can be identified on the basis of a low nuclear:cytoplasmic ratio, loss of the brush border and a mesen chymal phenotype. However, these features could also indicate the dedifferentiation of preexisting tubular cells that survived the original insult. 1 In support of the dediffer entiation model, vimentin and neural cell adhesion molecule (NCAM), which are both expressed in the metanephric mesen chyme during kidney development but not in the mature nephron, are reexpressed in proliferating and migrating proximal tubule cells during the repair process, sug gesting the readoption of an intermediate mesenchymallike phenotype. 3, 21, 22 As discussed above, little controversy remains over the tubular location of the cells that contribute to tubular repair in response to AKI. However, the debate as to whether this repair process involves a resident stem cell population or the dedifferentiation of existing cells has done little to address how this repair process might be harnessed clinically. What is clear is that although this reparative response occurs, it is not efficient on many occasions, notably in the setting of chronic kidney injury. Indeed, repeated and targeted injury of the tubular cells using a genetically inducible diphtheria toxin model argues strongly that repeated injury leads to an altered proliferative response, which results in cell cycle arrest and the generation of profibrotic factors, leading to interstitial fibrosis. [23] [24] [25] The successful iso lation and redelivery of 'tubular progeni tors' for the treatment of kidney disease, even with optimization of markers for their iso lation and protocols for their efficient expansion without alteration of their cel lular phenotype, will require an under standing of why this shift in the cellular response to repeated injury occurs in vivo. Refocusing on the interaction between the tubular compartment and its surrounding renal interstitium enables historical evi dence from experimental nephrology to be integrated with current understanding of the biology of progenitor cells.
Interstitial components
Label-retaining cells Stem cell populations outside the tubular compartment may not directly contribute cells for reepithelialization of the tubule; however, several clues point towards the existence of progenitor or stem cell popu lations in the renal interstitium that could influence tubular repair. One of the first observations of a stem cell population in the kidney was by Oliver et al. 4 who found that the renal papilla of adult rodents contains longterm labelretaining cells (LRCs) that persist throughout the life of the animal but quickly enter the cell cycle and dis appear from the papilla during recovery from ischaemia. Notably, papillary LRCs were only observed when a pulse of bromodeoxy uridine (BrdU; a synthetic nucleoside that labels dividing cells) was delivered in the immediate neonatal period. BrdU pulsechase studies performed after the neo natal period suggest that postnatal LRCs are located in the nephron epithelium. 26 Although not dismissing a subsequent role for papillary LRCs in response to injury, these cells may simply enter a state of qui escence in the immediate neonatal period. 27 Of note, these predominantly interstitial LRCs were capable of incorporating into renal tubules in response to acute injury, suggesting that these cells participate in renal repair. 4 The lack of evidence for a contribution of nontubular cell types to tubular repair seen in the studies that we discussed earlier could indicate that this event is either rare or only evoked under specific conditions of damage. 4 Another renal papillary subpopulation with stemcelllike properties has also been reported based on expression of renal telomerase reverse transcriptase (Tert). 28 Although described as predominantly epi thelial, up to 5% of Tert + cells are interstitial. However, unlike the previously described papillary interstitial LRCs, the Tert + cell population did not proliferate or migrate in response to ischaemic injury. 28 The
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Renal mesenchymal stromal cells The features of LRCs described above are very similar to those of MSCs in the bone marrow. 29, 30 Although initially isolated and most comprehensively characterized from bone marrow, MSCs can be isolated from almost all organs or tissue, including adipose, muscle, placenta, heart and pan creas, where the commonality of marker expression suggests that MSCs are present within the perivascular compartment of these organs. A 2012 study identified and characterized MSCs from the kidney and compared these with MSCs from bone marrow and heart. Despite considerable functional and phenotypic congruence between these MSC populations, kidney MSCs had distinct gene and protein expres sion profiles, suggesting the possibility of additional or distinct biological activities. 31 The precise role of these cells in normal renal homeostasis remains to be resolved.
Immune cells
Circulating immune cells, including haematopoietic progenitors and mature cells such as dendritic cells and macro phages, are also a prominent compo nent of the renal interstitium. The role of macro phages in renal repair is of particular interest because they can exhibit distinctly different functional phenotypes, and can be polarized towards proinflammatory (M1 macrophages) and tissuereparative (M2 macrophages) phenotypes. Indeed, evidence exists for the presence of a tissue macrophage population in the developing kidney before the formation of the first nephrons. 18 These tissue macrophages support nephrogenesis in response to macrophage colonystimulating factor 1 (CSF1) before migrating to the peritubular interstitium of the adult kidney. In the peri tubular interstitium they have been shown to mediate tissue repair in response to AKI by adopting an M2 phenotype and produ cing a cytokine environment that supports tubular repair and proliferation rather than inflammation. 32 Genetic or pharma cological blockade of CSF1 decreases M2 polarization and subsequently inhibits recovery from AKI. 33 Of note, this homeo static role of the immune system in situ is modulated by perivascular stromal cells and/or pericytes that, in concert with the endothelium, guide the migration and functional polarization of immune cells. 34, 35 It is tempting to speculate that the immunemodulating effects observed after administration of exogenous MSCs to experimental models are related, at least in part, to the role of perivascular stromal cells in tissue homeostasis.
Fibrosis versus regeneration
Another important aspect of perivascular stromal cell (tissue MSC) function is its role in the stabilization of endothelial cells and hence the microcirculatory vascular bed. 36 This role could be critical in the reparative capacity of the kidney. Typically, CKD is associated with microvascular rarefac tion and ischaemia. 37 Perivascular stromal cells signal to the endothelium through proteoglycans and cytokines, similar to the way in which bone marrow MSCs signal to the endothelium in the vascu lar niche. 38 For example, angiopoietin 1 signalling by perivascular stromal cells regulates endothelial cell quiescence and survival. 36 Activated endothelial cells produce angio poietin2, which competes with angio poietin1 for binding to the endothelial angiopoietin1 receptor (Tie2), and disrupts the functional unity between perivascular stromal cells and endothelial cells. One consequence of this disruption is inflammatory angiogenesis which, if vascular restabilization does not occur, can result in rarefaction and permanent tissue ischaemia. The seminal research by Humphreys et al. demonstrated that under these conditions, perivascular stromal cells can transform into myofibroblasts and contribute to renal fibrosis. 39 Interestingly, under inflammatory conditions, tissue stromal cells may also be derived from circulating haematopoietic cells that are recruited to sites of endo thelial injury and vascular remodelling, further under scoring the complex modulatory role that the immune system exerts on tissue regener ation. 40 These observations illus trate that both resident stromal cell popu lations and a population of haematopoietic cells in flux exist in the kidney, and that they confer important cues for the regula tion of both inflammation and repair. An intimate spatial and physical relationship exists between the key players-the endo thelium, the tissue MSC, the transmigrating immune cells and the tubular epitheliumin this complex reparative or regenera tive response (Figure 2 ). We suggest that understanding the (patho)physiological inter actions between these cells holds the key to understanding the regenera tion of renal tissue and that a reductionist approach defies the concept of an integrated regulatory process.
Translation to therapy
Bone marrow mononuclear cells The presence of the abovementioned cell types either within, or able to be recruited to, the renal interstitium to positively influ ence tubular epithelial repair raises the question as to whether administration of one or more of these cell populations to a patient could influence renal repair. Initial studies focused on the use of bone marrow mononuclear cells. Early experimental data reported beneficial effects of these cells in rodent models; however, the process of renal repair is complex, as is the infused cell population. The delivery of unfraction ated mono nuclear cells may also result in the infusion of cells that could potentially attain an inflammatory phenotype, depend ing on local environmental cues (reviewed in detail elsewhere 41 ). Interestingly, initial clinical studies in the field of cardiology seemed to demonstrate the value of mono nuclear cell infusions on cardiac function; however, three randomized controlled studies could not reproduce the beneficial effects. [42] [43] [44] The lack of benefit reported by these randomized studies raises two possi bilities: that the mononuclear cells do not affect cardiac function, or that the rand omized trials used a cell product that did not have regenerative capacity. Indeed, the large trials did not verify functional activ ity before infusing the mononuclear cells. In addition, the cell preparation used in the TIME study contained heparin at a dose that has been shown to impair the migra tory capacity of mononuclear cells. 40 Such differences in cell preparations are known to substantially influence mononuclear cell potency.
Use of MSCs
The focus of translational studies is now shifting toward the use of MSCs. Independent of their tissue of origin, MSCs synthesize soluble and paracrine factors that promote stemcell maintenance, including angiopoietins, vascular endo thelial growth factor, transforming growth factorβ1, insulin like growth factor1 (IGF1) and hepatocyte growth factor. Soluble factors secreted by these MSCs seem to be important for their reno protective properties. 45, 46 MSCs also have strong immunoregulatory effects. They can inhibit Tcell proliferation in vitro and skew T cells and macrophages towards a regulatory phenotype. 47 One of the few identifying markers of MSCs, the surface ectonucleotidase CD73, is a key factor in the metabolism of proinflammatory ATP (derived from cell debris, for example) to antiinflammatory adenosine. 48 In addition, MSCs were recently found to produce and secrete microvesicles that confer protection from tubular injury. 49, 50 In particular, the transfer of mRNAs and microRNAs derived from MSCs might induce phenotypic and functional changes in recipient cells and promote the activation of regenerative processes. 51 MSCs do not seem, however, to become directly involved in tubular epi thelial regeneration. Experiments in which MSCs were administered to animal models of AKI showed amelioration of injury, but did not show integration of MSCs into the tubular compartment.
Multiple studies have demonstrated that the administration of exogenous MSCs to experimental models of AKI and CKD exerts a beneficial effect on renal function (reviewed elsewhere 52 ). These studies include experimental models of acute ischaemic and toxic kidney injury, in which the beneficial effects of infused MSCs on recovery seemed to depend on the release of trophic factors such as IGF1, as well as chronic immune mediated injury, in which the effects of MSCs were related to their immuno suppressive actions. 46, 53 The timing and route of MSC delivery are important factors that deter mine the functional outcome in animal studies. Arterial delivery of MSCs, use of the renal ischaemia-reperfusion injury model, injection of a high number of MSCs, and injection of MSCs at least 1 day after injury (after initiation of the inflammatory response), positively influ ence kidney function. 52 Preclinical studies have also revealed that MSCs remain in the circulation only for a very short period of time (days), 6, 33, 54 whereas the thera peutic effect is preserved over a longer period of time (weeks). 6 This observation may reduce concerns regarding the potential of untoward MSC differentiation and tumour development. Indeed, although one report exists of adipogenic maldifferentiation in an animal study, 55 there have been no reports of tumourigenesis or maldifferen tiation of MSCs in clinical studies in which MSCs have been delivered to treat patients with conditions as varied as graftversus host disease, inflammatory bowel disease and cardiac disease. 56 Clinical MSC trials The findings described above were the basis for the first clinical studies of MSCs in patients with AKI and kidney trans plant recipients. One phase I clinical trial administered allogeneic bonemarrow derived MSCs to 16 patients at high risk of AKI while undergoing onpump cardiac surgery. 7 This trial was primarily a safety study, and from that perspective no adverse effects of MSCs were observed. To enable a preliminary assessment of therapeutic efficacy, trial participants were matched to a cohort of historical controls from the same institution where the phase I study was conducted. Just two of 16 (12.5%) MSCtreated patients developed AKI com pared with 19 of 64 (29.7%) of the historical controls. The length of stay in hospital was significantly reduced in the MSCtreated patients compared with the historical controls. These data have enabled the biotech company, AlloCure, to initiate a phase II study to assess the efficacy of MSCs as a treatment for AKI in individuals undergoing cardiac surgery. 57 As MSCs have important immuno modulatory properties, they have also been used to treat immunemediated renal disease, in particular that occurring after kidney transplantation. In a 2012 study, it was suggested that the infusion of auto logous MSCs could serve as an alterna tive to the antiIL2 receptor antibody for induction therapy in adults undergoing living related donor kidney transplanta tion. 58 Modulation of the immune system is also key in tissue regeneration; therefore, it is of interest that findings from our own phase I study indicate that MSCs admin istered to patients with endstage renal disease may reduce tubulointerstitial inflammation and fibrosis. 59 Although promising, the findings of these first clinical trials and observations with MSCs in the field of kidney disease highlight several important challenges. The isolation of MSCs for clinical trials, whether the cells are autologous or allo genic, is a relatively crude process result ing in an undoubtedly heterogenous cell population. Despite some concern that the presence of renal failure may affect the function of autologous MSCs, data show that MSCs from uraemic patients are as efficient with respect to their immuno suppressive properties as those from healthy individuals. 60 Whether adopted as an autologous or allogenic procedure, the heterogeneity of transplanted cells is a challenge in clinical trials. The avail ability of an offtheshelf product might overcome some of the logistic and regula tory limitations associated with the use of autologous MSCs, provide greater scope for improved cell sorting on the basis of specific functional properties, and allow standardization of the biological potency of MSCs. Standardization of the biological potency of MSCs is currently limited by the lack of an assay and represents a major hurdle for the development of (multi centre) trials. One can even question the necessity of administering the MSCs to patients. Proofofconcept studies show that microvesicles or conditioned media derived from MSCs may possess some of the therapeutic potential of MSCs. 49 Such an approach would avoid the complex pro duction and regulatory processes involved in developing MSC therapies. However, for MSCderived products to be as effective as cell therapy, a much better understanding of the mechanisms of action of MSCs is required. A greater understanding of the actions of such cells in postnatal tubular cell turnover and tissue homeostasis than we presently have is also critical.
Conclusions
The kidney clearly has an innate capa city for regeneration, which can in fact be quite impressive in the presence of, for example, tubular necrosis. A tight balance exists between the processes of regener ation and fibrotic repair, which is governed by both resident cells and migrating immune cells. The recognition that tissue stromal cells are key regulators of this balance could present new therapeutic opportunities to support the process of renal regener ation. Although the administration of exogenous MSCs as an approach to support some of the physiological regulatory potential of endo genous renal MSCs might seem oversimplified, robust in vivo evidence from experimental and clinical studies indicates that these cells can indeed stimulate kidney regeneration. 52, 60 Challenges remain, however, in developing MSCs as a clinical therapy.
We postulate that preservation of innate kidney regeneration is ultimately about resetting the response of the tubulointersti tial compartment to injury. The first prior ity is to better understand the regenerative potential of the tubular compartment itself. Perhaps of greater interest than the debate over whether the innate regenerative capa city of the kidney involves local stem cells or dedifferentiated epithelial cells is the fact that tubular epithelial cells express key receptors involved in responses to secreted ligands (for example CXC receptor type 4, the receptor for stromal cellderived factor 1). Some of the ligands for these receptors are likely to be provided by cells surrounding the tubular compartment. 3 This observation not only increases the repertoire of markers with which specific interstitial and tubular cell populations can be functionally identified for analysis, but could also identify the factors that might be critical in driving or suppressing the repair response. The second priority is to understand how perivascular stromal cells and/or MSCs are involved in polarization of the immune system and stabilization of tissue homeostasis. Studies in which MSCs are administered to patients may serve as a useful platform to understand this complex biology; studies performed to date have already led to the identification of a wide variety of mechanisms of action of MSCs. Insights from these studies might surpass the clinical implications for MSCs as a cell based therapeutic approach and provide a fundamental understanding of the innate regenerative capacity of the kidney.
MSC therapy is typical of an emerg ing technology that faces uncertainties of a technological, financial, regulatory and strategic nature. Despite the limitations in our understanding of the biological pro cesses involved and difficulties in clinical translation, we propose that MSC therapy could provide important new insights that may help to alleviate the huge medical and societal challenges of CKD.
